Skip to main content

Table 5 Changes in NEI-VFQ-25 subscale scores from baseline to 12 months in each baseline vision group (N=69)

From: Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study

NEI VFQ-25 Subscale Decimal visual acuity
Below 0.5 Above 0.6
CFB 95%CI P value CFB 95%CI P value
Lower Upper Lower Upper
Overall 5.9 3.2 8.5 0.00003 6.8 3.8 9.9 0.00002
General health 0.2 −5.2 5.7 0.93339 −1.7 −8.0 4.5 0.5804
General vision 9.3 4.0 14.5 0.00059 12.5 6.5 18.5 0.00006
Ocular pain −0.1 −4.1 3.8 0.95172 0.9 −3.6 5.4 0.68663
Near activities 4.5 −0.8 9.9 0.09667 8.6 2.6 14.6 0.00561
Distance activities 2.9 −1.5 7.2 0.19592 5.7 0.7 10.6 0.02534
Social functioning 4.9 0.6 9.3 0.02557 7.0 2.1 11.9 0.00528
Mental health 16.8 11.8 21.7 0 6.1 0.5 11.7 0.03438
Role difficulties 11.4 5.3 17.5 0.00028 8.6 1.7 15.5 0.01487
Dependency 7.7 3.1 12.3 0.00116 5.0 −0.3 10.2 0.06256
Driving −7.3 −14.9 0.3 0.05868 5.2 −2.1 12.6 0.16173
Color vision 2.1 −2.5 6.7 0.36726 3.8 −1.4 9.1 0.15108
Peripheral vision 3.9 −2.7 10.5 0.24607 6.8 −0.6 14.1 0.06986
  1. CFB Change from baseline, CI confidence interval, NEI-VFQ-25 25-item National Eye Institute Visual Function Questionnaire
\